NCT03102060 is a NA clinical trial of Dietary Intervention in Graft Versus Host Disease, sponsored by Rutgers, The State University of New Jersey.

Who is sponsoring NCT03102060?

NCT03102060 is sponsored by Rutgers, The State University of New Jersey.

What drugs are being tested in NCT03102060?

Interventions in NCT03102060: Dietary Intervention, Laboratory Biomarker Analysis.

What condition does NCT03102060 study?

NCT03102060 studies Graft Versus Host Disease, Hematopoietic Cell Transplantation Recipient.

Is NCT03102060 still recruiting?

NCT03102060 is currently terminated. Last updated 23 August 2021.

Last reviewed 2021-08-23 · How we verify

NCT03102060

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant

Terminated NA Last updated 23 August 2021

What this trial tests

NA trial testing Dietary Intervention in Graft Versus Host Disease in 7 participants. Terminated before completion.

Timeline

22 August 2017

Primary endpoint
11 June 2018

11 June 2018

Quick facts

Lead sponsor	Rutgers, The State University of New Jersey
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	7
Start date	22 August 2017
Primary completion	11 June 2018
Estimated completion	11 June 2018
Sites	1 location across United States

Drugs / interventions tested

Dietary Intervention
Laboratory Biomarker Analysis — full drug profile →

Conditions studied

Graft Versus Host Disease — all drugs for Graft Versus Host Disease →
Hematopoietic Cell Transplantation Recipient — all drugs for Hematopoietic Cell Transplantation Recipient →

Sponsor

Rutgers, The State University of New Jersey

Who can join

18 and older, any sex, with Graft Versus Host Disease or Hematopoietic Cell Transplantation Recipient. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot clinical trial studies how well a gluten free diet works in preventing graft versus host disease in patients who are undergoing a donor stem cell transplant. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft versus host disease). A gluten free diet may decrease intestinal inflammation and graft versus host disease in patients who are undergoing a donor stem cell transplant.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Gut microbiota injury in allogeneic haematopoietic stem cell transplantation.
Shono Y, van den Brink MRM. · · 2018 · cited 225× · PMID 29449660 · DOI 10.1038/nrc.2018.10
The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future.
Andermann TM, Peled JU, Ho C, Reddy P, et al · · 2018 · cited 84× · PMID 29471034 · DOI 10.1016/j.bbmt.2018.02.009
Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation.
Hamilton BK. · · 2018 · cited 52× · PMID 30504315 · DOI 10.1182/asheducation-2018.1.228
Gut microbiota, microbiota-derived metabolites, and graft-versus-host disease.
Yue X, Zhou H, Wang S, Chen X, et al · · 2024 · cited 26× · PMID 38239049 · DOI 10.1002/cam4.6799
Microbiome Anomalies in Allogeneic Hematopoietic Cell Transplantation.
Schwabkey ZI, Jenq RR. · · 2020 · cited 17× · PMID 31986084 · DOI 10.1146/annurev-med-052918-122440

Verify or expand the search:

Other trials of Dietary Intervention

Trials testing the same drug.

NCT06391099 — Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic · NA · recruiting
NCT07091864 — Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma · NA · recruiting
NCT06954584 — Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovari · Phase 3 · recruiting
NCT06900439 — Exploring Glycemic Responses Through Continuous Monitoring in a Healthy Population · NA · completed
NCT06336902 — Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorec · Phase 1 · recruiting

Other recruiting trials for Graft Versus Host Disease

Currently open trials in the same condition.

NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
NCT07006506 — A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant · Phase 2 · recruiting
NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
NCT06705062 — Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment · Phase 3 · recruiting
NCT06252870 — Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-trans · Phase 2 · recruiting

Other Rutgers, The State University of New Jersey trials

Trials by the same sponsor.

NCT07243886 — Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and/or Diabetes (MOM-HD) · NA · not yet recruiting
NCT06955130 — Lactate and Glycerol Contribution to Gluconeogenesis · NA · not yet recruiting
NCT06822010 — SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma · Phase 2 · not yet recruiting
NCT07525011 — Comparative Study of Denture Fabrication Techniques · NA · not yet recruiting
NCT06834204 — Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03102060 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rutgers, The State University of New Jersey
Last refreshed: 23 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03102060.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing